BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 25135867)

  • 1. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C.
    Simon TG; King LY; Zheng H; Chung RT
    J Hepatol; 2015 Jan; 62(1):18-23. PubMed ID: 25135867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
    Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
    Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.
    Chang FM; Wang YP; Lang HC; Tsai CF; Hou MC; Lee FY; Lu CL
    Hepatology; 2017 Sep; 66(3):896-907. PubMed ID: 28318053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.
    Simon TG; Bonilla H; Yan P; Chung RT; Butt AA
    Hepatology; 2016 Jul; 64(1):47-57. PubMed ID: 26891205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.
    Hoefs JC; Shiffman ML; Goodman ZD; Kleiner DE; Dienstag JL; Stoddard AM;
    Gastroenterology; 2011 Sep; 141(3):900-908.e1-2. PubMed ID: 21699796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.
    Yang YH; Chen WC; Tsan YT; Chen MJ; Shih WT; Tsai YH; Chen PC
    J Hepatol; 2015 Nov; 63(5):1111-7. PubMed ID: 26196278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis.
    Zheng YX; Zhou PC; Zhou RR; Fan XG
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):759-766. PubMed ID: 28240613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort.
    Abu Dayyeh BK; Yang M; Dienstag JL; Chung RT
    Dig Dis Sci; 2011 Feb; 56(2):564-8. PubMed ID: 21136163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins Are Associated With a Decreased Risk of Severe Liver Disease in Individuals With Noncirrhotic Chronic Liver Disease.
    Sharma R; Simon TG; Hagström H; Lochhead P; Roelstraete B; Söderling J; Verna EC; Emond J; Ludvigsson JF
    Clin Gastroenterol Hepatol; 2024 Apr; 22(4):749-759.e19. PubMed ID: 37121528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes.
    Simon TG; Butt AA
    World J Gastroenterol; 2015 Jul; 21(27):8293-303. PubMed ID: 26217081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of steatosis on progression of fibrosis and virological response in chronic hepatitis C cases.
    Rafi H; Kabbaj N; Salihoun M; Amrani L; Acharki M; Guedira M; Nya M; Amrani N
    Arab J Gastroenterol; 2011 Sep; 12(3):136-8. PubMed ID: 22055591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis.
    Kamal S; Khan MA; Seth A; Cholankeril G; Gupta D; Singh U; Kamal F; Howden CW; Stave C; Nair S; Satapathy SK; Ahmed A
    Am J Gastroenterol; 2017 Oct; 112(10):1495-1505. PubMed ID: 28585556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis.
    Mohanty A; Tate JP; Garcia-Tsao G
    Gastroenterology; 2016 Feb; 150(2):430-40.e1. PubMed ID: 26484707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis.
    Gordon A; McLean CA; Pedersen JS; Bailey MJ; Roberts SK
    J Hepatol; 2005 Jul; 43(1):38-44. PubMed ID: 15876468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.
    Morishima C; Shiffman ML; Dienstag JL; Lindsay KL; Szabo G; Everson GT; Lok AS; Di Bisceglie AM; Ghany MG; Naishadham D; Morgan TR; Wright EC;
    Am J Gastroenterol; 2012 Sep; 107(9):1388-98. PubMed ID: 22688849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection.
    Chen Yi Mei SLG; Thompson AJ; Christensen B; Cunningham G; McDonald L; Bell S; Iser D; Nguyen T; Desmond PV
    PLoS One; 2017; 12(10):e0185609. PubMed ID: 29065124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis.
    Noureddin M; Wright EC; Alter HJ; Clark S; Thomas E; Chen R; Zhao X; Conry-Cantilena C; Kleiner DE; Liang TJ; Ghany MG
    Hepatology; 2013 Nov; 58(5):1548-57. PubMed ID: 23703931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.
    Lok AS; Everhart JE; Wright EC; Di Bisceglie AM; Kim HY; Sterling RK; Everson GT; Lindsay KL; Lee WM; Bonkovsky HL; Dienstag JL; Ghany MG; Morishima C; Morgan TR;
    Gastroenterology; 2011 Mar; 140(3):840-9; quiz e12. PubMed ID: 21129375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
    Lok AS; Everhart JE; Chung RT; Kim HY; Everson GT; Hoefs JC; Greenson JK; Sterling RK; Lindsay KL; Lee WM; Di Bisceglie AM; Bonkovsky HL; Ghany MG; Morishima C;
    Hepatology; 2009 Jun; 49(6):1828-37. PubMed ID: 19291787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.
    Zarski JP; Sturm N; Desmorat H; Melin P; Raabe JJ; Bonny C; Sogni P; Pinta A; Rouanet S; Babany G; Cheveau A; Chevallier M
    Liver Int; 2010 Aug; 30(7):1049-58. PubMed ID: 20492512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.